中文摘要：

在非小细胞肺癌（non—small cell lung cancer，NSCLC）中已发现棘皮动物微管相关蛋白样4（echinoderm microtubule—associated protein—like4，EML4）和间变性淋巴瘤激酶（anaplastic lymphoma kinase，ALK）的融合基因。在不吸烟的NSCLC患者中大多可检测出EML4-ALK，其具有独特的病理学特征。EML4一ALK在体内外均有致癌性。ALK抑制剂（crizotinib）在EML4-ALK阳性的NSCLC患者中己取得较好的治疗效果。本综述重点阐述NSCLC中EML4-ALK的生物学特性、临床特征和治疗。

英文摘要：

The fusion gene between echinoderm EMI4 （microtubule-associated protein-like 4） and AI_K （anaplastic lymphoma kinase） has been identified in non-small cell lung cancer （NSCLC）. EML4-ALK is most commonly detected in never smokers with NSCLC and has unique pathologic features. EML4- ALK is oncogenic both in vitro and in vitro. ALK inhibitor （crizotinib） has demonstrated a remarkable clinical efficacy in EML4-ALK-positive NSCLC patients. This review emphasizes the biological and clinical characteristics and the therapeutic application of EML4-ALK in NSCLC.